The Dutch biotech’s SureTACs platform targets membrane proteins that have long eluded conventional drug discovery by engineering them out of existence rather than blocking them. Biovance Capital joins as new co-lead alongside Kurma Partners in a final close that brings the oversubscribed seed round to €17 million. Most drugs work by blocking proteins. They attach […]This story continues at The Next Web